- Home
- FRME vs BEAM Comparison
FRME vs BEAM Comparison
Compare FRME & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- BEAM
- Stock Information
- Founded
- FRME 1893
- BEAM 2017
- Country
- FRME United States
- BEAM United States
- Employees
- FRME N/A
- BEAM N/A
- Industry
- FRME Major Banks
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRME Finance
- BEAM Health Care
- Exchange
- FRME Nasdaq
- BEAM Nasdaq
- Market Cap
- FRME 2.1B
- BEAM 1.6B
- IPO Year
- FRME N/A
- BEAM 2020
- Fundamental
- Price
- FRME $39.76
- BEAM $17.59
- Analyst Decision
- FRME Buy
- BEAM Strong Buy
- Analyst Count
- FRME 4
- BEAM 11
- Target Price
- FRME $44.75
- BEAM $48.90
- AVG Volume (30 Days)
- FRME 359.9K
- BEAM 1.9M
- Earning Date
- FRME 07-23-2025
- BEAM 08-05-2025
- Dividend Yield
- FRME 3.76%
- BEAM N/A
- EPS Growth
- FRME 2.61
- BEAM N/A
- EPS
- FRME 3.55
- BEAM N/A
- Revenue
- FRME $615,411,000.00
- BEAM $63,578,000.00
- Revenue This Year
- FRME $15.14
- BEAM N/A
- Revenue Next Year
- FRME $5.03
- BEAM $8.82
- P/E Ratio
- FRME $10.79
- BEAM N/A
- Revenue Growth
- FRME N/A
- BEAM N/A
- 52 Week Low
- FRME $32.28
- BEAM $13.53
- 52 Week High
- FRME $46.13
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- FRME 65.97
- BEAM 45.97
- Support Level
- FRME $35.28
- BEAM $16.49
- Resistance Level
- FRME $37.82
- BEAM $17.73
- Average True Range (ATR)
- FRME 1.13
- BEAM 0.87
- MACD
- FRME 0.35
- BEAM 0.02
- Stochastic Oscillator
- FRME 90.82
- BEAM 29.91
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.